Cite

    Solomon, J. et al. (2023). Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 11 (1), pp. 87-96. [Online].